Abstract:Background Diagnosis of colorectal cancer (CRC) during early stages can greatly improve patient outcome. Although technical advances in the field of genomics and proteomics have identified a number of candidate biomarkers for non-invasive screening and diagnosis, developing more sensitive and specific methods with improved cost-effectiveness and patient compliance has tremendous potential to help combat the disease. Methods We enrolled three cohorts of 479 subjects, including 226 CRC cases, 197 healthy controls, and 56 advanced precancerous lesions (APC). In the discovery cohort, we used quantitative mass spectrometry to measure the expression profile of plasma proteins and applied machine-learning to select candidate proteins. We then developed a targeted mass spectrometry assay to measure plasma concentrations of seven proteins and a logistic regression classifier to distinguish CRC from healthy subjects. The classifier was further validated using two independent cohorts. Results The seven-protein panel consisted of leucine rich alpha-2-glycoprotein 1 (LRG1), complement C9 (C9), insulin-like growth factor binding protein 2 (IGFBP2), carnosine dipeptidase 1 (CNDP1), inter-alpha-trypsin inhibitor heavy chain 3 (ITIH3), serpin family A member 1 (SERPINA1), and alpha-1-acid glycoprotein 1 (ORM1). The panel classified CRC and healthy subjects with high accuracy, since the area under curve (AUC) of the training and testing cohort reached 0.954 and 0.958. The AUC of the two independent validation cohorts was 0.905 and 0.909. In one validation cohort, the panel had an overall sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of 89.9%, 81.8%, 89.2%, and 82.9%, respectively. In another blinded validation cohort, the panel classified CRC from healthy subjects with a sensitivity of 81.5%, specificity of 97.9%, and overall accuracy of 92.0%. Finally, the panel was able to detect APC with a sensitivity of 49%. Conclusions This seven-protein classifier is a clear improvement compared to previously published blood-based protein biomarkers for detecting early-stage CRC, and is of translational potential to develop into a clinically useful assay.

Lipid Profiling for Early Diagnosis and Progression of Colorectal Cancer Using Direct-Infusion Electrospray Ionization Fourier Transform Ion Cyclotron Resonance Mass Spectrometry.

Ultra-Performance Liquid Chromatography Coupled with Quadrupole Time-Of-Flight Mass Spectrometry-Based Metabolic Profiling of Human Serum Prior to and Following Radical Resection of Colorectal Carcinoma

Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS.

Metabolomic Profile for the Early Detection of Coronary Artery Disease by Using UPLC-QTOF/MS.

Metabolic-Dysregulation-Based Ieesi-Ms Reveals Potential Biomarkers Associated with Early-Stage and Progressive Colorectal Cancer.

A plasma lipidomics strategy reveals perturbed lipid metabolic pathways and potential lipid biomarkers of human colorectal cancer.

A Conjunctive Lipidomic Approach Reveals Plasma Ethanolamine Plasmalogens and Fatty Acids As Early Diagnostic Biomarkers for Colorectal Cancer Patients

UHPLC-HRMS–based serum lipisdomics reveals novel biomarkers to assist in the discrimination between colorectal adenoma and cancer

Identification of EFEMP2 as a serum biomarker for the early detection of colorectal cancer with lectin affinity capture assisted secretome analysis of cultured fresh tissues.

Metabolically Active Zones Involving Fatty Acid Elongation Delineated by DESI-MSI Correlate with Pathological and Prognostic Features of Colorectal Cancer

Characterization of the Fatty Acid Metabolism in Colorectal Cancer to Guide Clinical Therapy

A Proteomic Classifier Panel for Early Screening of Colorectal Cancer: a Case Control Study

LC-MS-based Lipid Profile in Colorectal Cancer Patients: TAGs Are the Main Disturbed Lipid Markers of Colorectal Cancer Progression.

Molecular Characterization of Advanced Colorectal Cancer Using Serum Proteomics and Metabolomics

Untargeted GC-MS-Based Metabolomics for Early Detection of Colorectal Cancer

Discovery of Potential Lipid Biomarkers for Human Colorectal Cancer by In-Capillary Extraction Nanoelectrospray Ionization Mass Spectrometry.

In-depth mapping carboxylic acid metabolome reveals the potential biomarkers in colorectal cancer through characteristic fragment ions and metabolic flux

Novel proteomic strategy reveal combined α1 antitrypsin and cathepsin D as biomarkers for colorectal cancer early screening

Colorectal Cancer Detection Using Targeted LC-MS Metabolic Profiling

[Study on Specific Metabonomic Profiling of Serum from Colorectal Cancer Patients by Gas Chromatography-Mass Spectrometry].

Distinct Plasma Molecular Profiles Between Early-onset and Late-onset Colorectal Cancer Patients Revealed by Metabolic and Lipidomic Analyses